JP2007538024A5 - - Google Patents

Download PDF

Info

Publication number
JP2007538024A5
JP2007538024A5 JP2007517041A JP2007517041A JP2007538024A5 JP 2007538024 A5 JP2007538024 A5 JP 2007538024A5 JP 2007517041 A JP2007517041 A JP 2007517041A JP 2007517041 A JP2007517041 A JP 2007517041A JP 2007538024 A5 JP2007538024 A5 JP 2007538024A5
Authority
JP
Japan
Prior art keywords
group
alkyl
phenyl
cycloalkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007517041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007538024A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/005229 external-priority patent/WO2005110422A2/en
Publication of JP2007538024A publication Critical patent/JP2007538024A/ja
Publication of JP2007538024A5 publication Critical patent/JP2007538024A5/ja
Pending legal-status Critical Current

Links

JP2007517041A 2004-05-19 2005-05-13 アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物 Pending JP2007538024A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04011894 2004-05-19
PCT/EP2005/005229 WO2005110422A2 (en) 2004-05-19 2005-05-13 Treatment of diseases associated with altered level of amyloid beta peptides

Publications (2)

Publication Number Publication Date
JP2007538024A JP2007538024A (ja) 2007-12-27
JP2007538024A5 true JP2007538024A5 (https=) 2008-07-03

Family

ID=34979633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007517041A Pending JP2007538024A (ja) 2004-05-19 2005-05-13 アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物

Country Status (5)

Country Link
US (4) US7375220B2 (https=)
EP (1) EP1750719A2 (https=)
JP (1) JP2007538024A (https=)
CA (1) CA2567223A1 (https=)
WO (1) WO2005110422A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603404A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
CA2617294A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
EP1915339A1 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
CA2618019A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for the treatment of alzheimer's disease
US20100144681A1 (en) * 2005-08-11 2010-06-10 Klaus Fuchs Compounds for the treatment of alzheimer's disease
WO2007017510A2 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Isophthalsäurediamide zur behandlung der alzheimer erkrankung
KR20090117950A (ko) * 2007-03-08 2009-11-16 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절자 및 그것의 사용 방법
AU2008248129B8 (en) 2007-05-07 2013-05-30 Merck Sharp & Dohme Corp. Gamma secretase modulators
MX2009013130A (es) 2007-06-01 2010-01-15 Schering Corp Moduladores de gamma secretasa.
JP5495331B2 (ja) 2007-06-01 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション γセクレターゼ修飾因子
MX2010001506A (es) * 2007-08-06 2010-03-10 Schering Corp Moduladores de gamma secretasa.
WO2009032277A1 (en) 2007-09-06 2009-03-12 Schering Corporation Gamma secretase modulators
US8487099B2 (en) 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
EP2227471A1 (en) 2007-12-11 2010-09-15 Schering Corporation Gamma secretase modulators
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
RU2011123862A (ru) 2008-11-13 2012-12-20 Шеринг Корпорейшн Модуляторы гамма-секретазы
AU2009314205A1 (en) 2008-11-13 2010-05-20 Merck Sharp & Dohme Corp. Gamma secretase modulators
US20100159485A1 (en) * 2008-12-19 2010-06-24 Centre For Dna Fingerprinting And Diagnostics Detection of mycobacterium tuberculosis
JP2012513400A (ja) 2008-12-22 2012-06-14 シェーリング コーポレイション γ−セクレターゼ調節剤
US8759337B2 (en) 2008-12-22 2014-06-24 Merck Sharp & Dohme Corp. Gamma secretase modulators
US20100233156A1 (en) * 2009-03-09 2010-09-16 Georgetown University Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors
JP2012520875A (ja) * 2009-03-19 2012-09-10 ブリストル−マイヤーズ スクイブ カンパニー ベータアミロイドペプチド産生阻害剤としての新規アルファ−(n−スルホンアミド)アセトアミド化合物
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
US20120245158A1 (en) 2009-06-16 2012-09-27 Xianhai Huang Gamma secretase modulators
EP2443118A1 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
WO2012125720A2 (en) 2011-03-14 2012-09-20 University Of Louisville Research Foundation, Inc. Polypeptides having immunoactivating activity and methods of producing the same
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法
EP3313866B1 (en) 2015-06-29 2024-11-20 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer and promoting wound healing
US12343375B2 (en) 2021-02-09 2025-07-01 University Of Louisville Research Foundation, Inc. Spray dried formulation of a cholera toxin B subunit variant
CN118791377B (zh) * 2024-09-10 2025-02-07 山东国邦药业有限公司 一种2,4,5-三氟苯乙酸的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674876A (en) * 1969-06-09 1972-07-04 Pfizer Benzothiazine dioxides as lipid regulating agents
US3998954A (en) * 1971-02-05 1976-12-21 Pfizer Inc. 1,3(2H,4H)-Dioxoisoquinoline-4-carboxamides used as anti-inflammatory agents
US3891637A (en) * 1974-10-01 1975-06-24 Pfizer Process for the production of carboxamides of oxo-1,2-benzothiazine-1,1-dioxides
MC1135A1 (fr) * 1976-02-23 1977-11-18 Hoffmann La Roche Derives de thiazine
US4175085A (en) * 1976-02-23 1979-11-20 Hoffmann-La Roche Inc. Thienothiazine derivatives
LU78009A1 (de) * 1977-08-22 1979-05-23 Hoffmann La Roche Verfahren zur herstellung von thiazinderivaten
US4683306A (en) * 1984-07-13 1987-07-28 Yuhan Corporation Co., Ltd. Process for the preparation of 3,4-dihydro-2-substituted-2H-1,2-thiazine-carboxylic acid 1,1-dioxide derivatives
US5387742A (en) * 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
WO1992013069A1 (en) * 1991-01-21 1992-08-06 Imperial College Of Science, Technology & Medicine Test and model for alzheimer's disease
JPH05286941A (ja) * 1991-09-30 1993-11-02 Nippon Zeon Co Ltd ピリジン−2,6−ジオン誘導体
EP0620849B1 (en) 1992-01-07 2003-06-25 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
AU702293B2 (en) * 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
ATE530180T1 (de) * 1997-04-02 2011-11-15 Brigham & Womens Hospital Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
AU768473B2 (en) 1999-07-16 2003-12-11 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Novel aminobenzophenones
AU782386C (en) * 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
AU5702201A (en) 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
JP2005515407A (ja) * 2001-11-05 2005-05-26 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド アテローム硬化症の予後マーカーとしての可溶性cd40l(cd154)
WO2003088811A2 (en) * 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases

Similar Documents

Publication Publication Date Title
JP2007538024A5 (https=)
RU2317294C2 (ru) (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора
JP2006524660A5 (https=)
JP2011509309A5 (https=)
JP2013508279A5 (https=)
JP2011504903A5 (https=)
JP2006517591A5 (https=)
JP2007519649A5 (https=)
JP2014511891A5 (https=)
JP2005539088A5 (https=)
JP2014530900A5 (https=)
JP2011516511A5 (https=)
JP2016040288A5 (https=)
JP2010523522A5 (https=)
JP2008539267A5 (https=)
JP2012533546A5 (https=)
JP2008539268A5 (https=)
JP2007508360A5 (https=)
JP2013531070A5 (https=)
JP2017517538A5 (https=)
JP2012532883A5 (https=)
JP2007507494A5 (https=)
JP2010155827A5 (https=)
JP2019520344A5 (https=)
JP2013513607A5 (https=)